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Background
Our starting platform was based on a heterologous BCG
prime and MVA boost regimen delivering a common
immunogen called HIVA. In this study, we have i)
developed a BCG.HIVACAT strain containing an antibio-
tic free selection system (Cobra); ii) evaluated the speci-
fic HIV-1 immune responses induced after newborn
BALB/c mice immunization with BCG.HIVACAT prime
and MVA.HIVA.85A boost; iii) evaluated the specific-
TB immune responses induced after newborn BALB/c
mice immunization with BCG.HIVACAT prime and
MVA.HIVA.85A boost and iv) evaluated the influence
of age on specific HIV-1 immune responses using the
same vaccination schedule.
Methods
7-days-old newborn and 7-weeks-old adult mice were
either left unvaccinated or vaccinated subcutaneously
with 105 cfu of BCG.HIVACAT or BCGwt, and 16 weeks
later were boosted intramuscularly with 106 pfu MVA.
HIVA.85A. The mice were sacrificed 2 weeks later. The
HIV-1 and TB-specific cellular immune responses were
analyzed in spleen cells by intracellular cytokine staining
and IFN-g ELISPOT.
Results
The frequencies of TB-specific CD8 + T-cells producing
IFN-g (P11 stimulation), and spleen cells producing
IFN-g (P11, P15 and PPD stimulation), were higher in
BCG.HIVACAT or BCGwt primed and MVA.HIVA.85A
boosted mice compared with mice vaccinated with
MVA.HIVA.85A alone (i.e. 231, 108 and 24 sfu/106 PPD
stimulated splenocytes respectively). The specific HIV-1
immune responses (P18I10 stimulation) were lower in
BCG.HIVACAT or BCGwt primed and MVA.HIVA.85A
boosted mice compared with mice vaccinated with
MVA.HIVA.85A alone (i.e. 270, 276 and 412 sfu/106
P18I10 stimulated splenocytes respectively). When adult
and newborn mice were immunized using the same vac-
cination schedule, the HIV-1-specific immune responses
in adult mice were higher than in newborn mice (0.45%
vs 0.2% CD8+ T-cells producing IFN g).
Conclusion
In conclusion we demonstrated the immunogenicity of
BCG.HIVACAT and MVA.HIVA.85A in newborn mice but
additional experiments should be performed in newborn
mice testing different routes and doses that might provide
different levels of immunogenicity.
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